Erythropoietin in the UK: a setback for gene patents?
Crespi
R Stephen
RS
crespi@f2s.com
D004921:Erythropoietin / Q000191:economics / Q000627:therapeutic use*; D015316:Genetic Therapy / Q000331:legislation & jurisprudence* / Q000379:methods*; D016365:Liability, Legal; D010067:Ownership / Q000331:legislation & jurisprudence*; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D015202:Protein Engineering / Q000331:legislation & jurisprudence*; D011994:Recombinant Proteins; D006113:United Kingdom
D011994:Recombinant Proteins; D004921:Erythropoietin